)

Vertex Pharmaceuticals (VRTX) investor relations material
Vertex Pharmaceuticals Bank of America Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key catalysts and pipeline updates
Three ongoing commercial launches: LifTrak for cystic fibrosis, Casgevy for sickle cell disease and beta thalassemia, and Jurnavix for acute pain, marking a new phase of revenue and commercialization diversification.
Four ongoing phase 3 programs and a fifth to start soon, including diabetic peripheral neuropathy, immunoglobulin A nephropathy (IgAN), APOL1-mediated kidney disease, and primary membranous nephropathy.
Major enrollment milestones for enoxaparin in AMKD and POVI in IgAN expected by year-end, with data for POVI in IgAN anticipated in the first half of 2026.
Regulatory filings for POVI and Zomylacell in type 1 diabetes are possible in 2026.
Ongoing dispute with Royalty Pharma over LifTrak royalties, expected to resolve by end of 2026.
Cystic fibrosis franchise and growth drivers
Survival benefits from CFTR modulators are driving market growth, with approvals expanding to younger patients and new geographies.
LifTrak targets rare mutations and patients who discontinued previous therapies, offering once-daily dosing and a favorable side effect profile.
VX-522, an inhaled mRNA therapy, is in development for patients not producing CFTR protein.
Majority of LifTrak prescriptions are switches from Trikafta, with additional liver monitoring required in the U.S.
Next-generation VX-828 aims to bring more patients to carrier-level sweat chloride, with patient trials expected before year-end.
Pain franchise and Jurnavix launch
Jurnavix achieved unrestricted access for 85 million U.S. lives by August, with ongoing negotiations to expand coverage.
Jurnavix is positioned as a non-opioid with a clean side effect profile, used primarily at discharge for acute pain, with average script duration of 14 days.
Two phase 3 studies in diabetic peripheral neuropathy (DPN) are underway, with enrollment expected to complete in 2026.
Strategy for chronic pain label is evolving based on FDA feedback, with potential for combination therapies in the future.
Next Vertex Pharmaceuticals earnings date

Next Vertex Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage